Printer Friendly

MPI of Biochemistry, LDC and Qurient Close License Deal on a New Compound Against Metastatic Cancers.

Dortmund, Germany, March 14, 2013 --(PR.com)-- The Max Planck Institute of Biochemistry (MPIB), the Lead Discovery Center GmbH (LDC) and Qurient Co., Ltd have entered into a license agreement providing Qurient with world-wide, exclusive rights to a new kinase inhibitor for the treatment of metastatic cancer.

The lead compound belongs to a family of highly selective Axl kinase inhibitors that was jointly developed by LDC and Max-Planck researchers around Prof. Axel Ullrich at MPIB. Together they have shown that the new Axl kinase inhibitor interferes with key mechanisms of metastasis formation and significantly reduces the number of metastases in-vivo. The project originally emerged from a collaboration of MPIB with Vichem Chemie Research Ltd.

During the coming year, Qurient, LDC and MPIB will work closely together to ensure a smooth transition of the project into preclinical and clinical development at Qurient. The company plans to continue the project at least to clinical proof-of-concept before sublicensing it to a partner for further development and marketing. Under the terms of the agreement, LDC and MPIB will receive an upfront payment as well as milestone and royalty payments, in line with the project's progress.

About Qurient:

Starting operation in 2009, Qurient is a venture capital funded spin-off biotechnology company of Institut Pasteur Korea (IPK) and dedicated to developing novel therapeutics for unmet medical needs. Qurient has in-house expertise in research and development project management and operates in a large part as a development management company using its network of drug development capabilities.

Qurient works from discovery to human proof-of-concept programs, where transformation takes place from a high potential research program into a solid product portfolio. Further information available at: www.qurient.com

About LDC:

The Lead Discovery Center (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need.

With a world-class team of interdisciplinary scientists, drug discovery experts, pharmacologists and seasoned project managers, LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads that reach initial proof-of-concept in animals.

LDC sustains a long-term partnership with the Max Planck Society and closely collaborates with leading Max-Planck researchers such as Prof. Axel Ullrich on a portfolio of small molecule drug discovery projects with exceptional medical and commercial potential. Further information available at: www.lead-discovery.de

Contact Information:

Lead Discovery Center GmbH

Thomas Hegendorfer

4923197427002

Contact via Email

http://www.lead-discovery.de/

Otto-Hahn-Stra[sz]e 15

Dortmund

Germany
COPYRIGHT 2013 PR.com
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR.com (Press Releases)
Geographic Code:4EUGE
Date:Mar 14, 2013
Words:425
Previous Article:Abenity Empowers Human Resource Teams with Over 40 Employee Engagement Tools in New Back Office.
Next Article:William Peace University Announces Erskine Bowles as 2013 Commencement Speaker.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |